GlassScriptPhysician profile
Erlandas Ulozas
NPI 1699774158
$953.16
in general payments reported to CMS, 2019-2025
7 companies · $78.23 in 2025
The $78.23 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $93.79 · 2021: $247 · 2023: $228 · 2024: $306 · 2025: $78.23.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $588 · Education: $24.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $587.92 |
| Education | $24.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $255.03 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $236.57 | 2021-2023 | Farxiga |
| Baxter Healthcare | $218.20 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $123.68 | 2024 | Jardiance |
| Novo Nordisk INC | $55.32 | 2025 | Ozempic, Rybelsus |
| Otsuka America Pharmaceutical, INC. | $39.75 | 2024-2025 | Voyxact, Jynarque |
| Akebia Therapeutics INC | $24.61 | 2024 | Vafseo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erlandas Ulozas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.